HD-MED: A longitudinal, observational study to assess medication use, medication efficacy and the role of pharmacogenetics in Huntington’s Disease

eiden University Medical Center (investigator-initiated)0 个研究点目标入组 391 人开始时间: 待定最近更新: 2024年6月11日

试验速览

暂无简介。

•In order to be eligible to participate in this study, a subject must meet all of the following criteria: - A capacitated individual, aged = 18 years. - Genetically confirmed CAG-repeat expansion of = 36 in the HTT gene. - Either about to start with prescribed medication related to HD or already using one or more HD related drugs. HD-related drugs are drugs considered to treat symptoms that either are related to manifest HD or are prescribed in pre-motor manifest or prodromal HD stage for symptoms that may be attributed to HD. - Sufficient knowledge of the Dutch language to understand the subject information letter and sign the informed consent form.

•A potential subject who meets any of the following criteria will be excluded from participation in this study: - Any medical condition, in the view of the investigator, which might endanger subject’s safety and/or satisfactory participation in the study.

发起方

eiden University Medical Center (investigator-initiated)